<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-95 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-95</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-95</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-8.html">extraction-schema-8</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <p><strong>Paper ID:</strong> paper-d58dc176f66799d15d8064696436568efcd1d21e</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/d58dc176f66799d15d8064696436568efcd1d21e" target="_blank">When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> Solutions describing how to overcome cancer drug resistance are proposed; these include early detection during cancer initiation, monitoring of clinical drug response, novel anticancer drug and target metabolism, immunotherapy, and the emergence of spatial metabolomics.</p>
                <p><strong>Paper Abstract:</strong> Resistance to drug treatment is a critical barrier in cancer therapy. There is an unmet need to explore cancer hallmarks that can be targeted to overcome this resistance for therapeutic gain. Over time, metabolic reprogramming has been recognised as one hallmark that can be used to prevent therapeutic resistance. With the advent of metabolomics, targeting metabolic alterations in cancer cells and host patients represents an emerging therapeutic strategy for overcoming cancer drug resistance. Driven by technological and methodological advances in mass spectrometry imaging, spatial metabolomics involves the profiling of all the metabolites (metabolomics) so that the spatial information is captured bona fide within the sample. Spatial metabolomics offers an opportunity to demonstrate the drug-resistant tumor profile with metabolic heterogeneity, and also poses a data-mining challenge to reveal meaningful insights from high-dimensional spatial information. In this review, we discuss the latest progress, with the focus on currently available bulk, single-cell and spatial metabolomics technologies and their successful applications in pre-clinical and translational studies on cancer drug resistance. We provide a summary of metabolic mechanisms underlying cancer drug resistance from different aspects; these include the Warburg effect, altered amino acid/lipid/drug metabolism, generation of drug-resistant cancer stem cells, and immunosuppressive metabolism. Furthermore, we propose solutions describing how to overcome cancer drug resistance; these include early detection during cancer initiation, monitoring of clinical drug response, novel anticancer drug and target metabolism, immunotherapy, and the emergence of spatial metabolomics. We conclude by describing the perspectives on how spatial omics approaches (integrating spatial metabolomics) could be further developed to improve the management of drug resistance in cancer patients.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e95.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e95.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PD-1 + CTLA-4 blockade</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Combined PD-1 (nivolumab) and CTLA-4 (ipilimumab) immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Concurrent blockade of PD-1 and CTLA-4 to amplify anti-tumor T-cell activation and broaden antitumor immunity; cited in the review as a combination strategy that increases response rates and survival in metastatic melanoma and is proposed to help overcome immunotherapy resistance by converting 'cold' tumors into 'hot'.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-PD-1 + anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>general immunotherapy resistance / to increase response in metastatic melanoma (not specified as strictly acquired in the review)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Immunosuppressive tumor microenvironment with insufficient T-cell infiltration and multiple inhibitory checkpoints limiting effective antitumor T-cell responses (i.e., immune 'cold' tumors and overlapping inhibitory pathways).</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Dual checkpoint blockade (anti-PD-1 + anti-CTLA-4)</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>nivolumab + ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Blockade of two non-redundant immune checkpoints to increase T-cell activation, broaden the repertoire of tumor-reactive T cells, and convert immune-cold tumors into immune-hot microenvironments to improve response rates and survival.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>clinical trial (NEJM report cited)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>previously untreated metastatic melanoma patients (as cited in the review)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Review states combination resulted in higher response rates and improvements in survival compared to monotherapy; numeric endpoints not reported in the review (no ORR/PFS/OS values provided).</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective', 'publication_date_yy_mm': '2023-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e95.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e95.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>T-VEC + ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Talimogene laherparepvec (T-VEC) combined with ipilimumab (CTLA-4 blockade)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Combination of an intratumoral oncolytic virus (T-VEC) with CTLA-4 checkpoint blockade to enhance local antigen release and inflammation thereby augmenting systemic anti-tumor immune responses; cited in the review as a tested combination in unresectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor (anti-CTLA-4) combined with oncolytic virus immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>not specified (described as strategy to improve response / overcome immunological non-responsiveness)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>Insufficient tumor immunogenicity/poor antigen presentation and local immunosuppression; rationale is that T-VEC induces tumor cell lysis and antigen release and local inflammation to potentiate checkpoint blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Oncolytic virus + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>talimogene laherparepvec (T-VEC) + ipilimumab</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>Oncolytic virus-mediated tumor lysis increases antigen release and local inflammation, which may synergize with CTLA-4 blockade to generate or expand systemic antitumor T-cell responses and thus improve checkpoint efficacy.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>clinical trial (J Clin Oncol report cited)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>previously untreated, unresectable stage IIIBâ€“IV melanoma (as cited)</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective', 'publication_date_yy_mm': '2023-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e95.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e95.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma patients, including the mechanisms of resistance, the therapies combined, and the clinical or preclinical outcomes.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>BRAF inhibitor + immunotherapy</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>BRAF-targeted therapy (e.g., vemurafenib) combined with immune checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Combining BRAF-targeted agents with checkpoint inhibitors to exploit BRAF inhibition-induced increases in antigen and HLA expression, T-cell infiltration, and improved T-cell function, thereby converting the tumor microenvironment to an immune-favorable state and potentially countering adaptive resistance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>primary_immunotherapy</strong></td>
                            <td>immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4; review discusses immunotherapy in general)</td>
                        </tr>
                        <tr>
                            <td><strong>immunotherapy_class</strong></td>
                            <td>checkpoint inhibitor combined with targeted therapy (BRAF inhibitor)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_type</strong></td>
                            <td>adaptive/acquired resistance (adaptive resistance of tumor and limited durable disease control with targeted therapy alone is discussed)</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanism</strong></td>
                            <td>BRAFV600E-associated immune evasion including reduced antigen presentation (e.g., MHC class I internalization) and an immunosuppressive microenvironment that limits CD8+ T-cell recognition; adaptive resistance to targeted therapy and immune escape mechanisms are described.</td>
                        </tr>
                        <tr>
                            <td><strong>combination_strategy_name</strong></td>
                            <td>Targeted therapy (BRAF inhibitor) + checkpoint blockade</td>
                        </tr>
                        <tr>
                            <td><strong>combination_agents</strong></td>
                            <td>vemurafenib (BRAF inhibitor) + immune checkpoint inhibitor (e.g., anti-PD-1 or anti-CTLA-4) (the review mentions the class and examples but does not specify a particular checkpoint agent paired in a trial within the text).</td>
                        </tr>
                        <tr>
                            <td><strong>combination_rationale</strong></td>
                            <td>BRAF inhibition can increase tumor antigen and HLA expression, increase T-cell infiltration, reduce immunosuppressive cytokines, and improve T-cell function, thereby converting a 'cold' microenvironment into a 'hot' one and enhancing responsiveness to checkpoint blockade.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>clinical and translational studies cited (vemurafenib clinical data and translational immunologic analyses referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>BRAF-mutant melanoma patients</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_outcomes</strong></td>
                            <td>Review notes BRAF-targeted therapy alone provides limited durable disease control but creates favorable tumor microenvironment effects; no numeric combination trial outcomes are provided in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>biomarkers_predictive</strong></td>
                            <td>BRAF V600 mutation</td>
                        </tr>
                        <tr>
                            <td><strong>timing_sequence</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>toxicity_safety</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparison_to_monotherapy</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overcomes_resistance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective', 'publication_date_yy_mm': '2023-01'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma <em>(Rating: 2)</em></li>
                <li>Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma <em>(Rating: 2)</em></li>
                <li>Improved survival with vemurafenib in melanoma with BRAF V600E mutation <em>(Rating: 2)</em></li>
                <li>BRAFV600E co-ops a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>